Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis C

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 43 articles:
HTML format



Single Articles


    March 2024
  1. CHEN X, Dong S, Shi Y, Wu Z, et al
    Biosensor-based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C virus.
    J Med Virol. 2024;96:e29481.
    PubMed     Abstract available


  2. MIUMA S, Miyaaki H, Ichikawa T, Matsuzaki T, et al
    Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history.
    J Med Virol. 2024;96:e29432.
    PubMed     Abstract available


    February 2024
  3. CHEN B, Xu B, Cui HY, Ma ZH, et al
    Comparison of effectiveness and cost of different HCV testing strategies in high-risk populations in China.
    J Med Virol. 2024;96:e29433.
    PubMed     Abstract available


  4. LIU W, Li L, Yin M, Cao C, et al
    High-speed centrifugation rather than Lipoclear reagent can be used for removing the interference of lipemia on serological tests of infectious diseases: AIDS, hepatitis B, hepatitis C, and syphilis by chemiluminescent microparticle immunoassay.
    J Med Virol. 2024;96:e29385.
    PubMed     Abstract available


  5. LIU Y, Kim ES, Guo H
    Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures.
    J Med Virol. 2024;96:e29485.
    PubMed     Abstract available


    January 2024
  6. LI M, Wei Z, Su J, Wu X, et al
    Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.
    J Med Virol. 2024;96:e29405.
    PubMed     Abstract available


  7. ADHIKARI A, Abayasingam A, Brasher NA, Kim HN, et al
    Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes.
    J Med Virol. 2024;96:e29381.
    PubMed     Abstract available


    December 2023
  8. ABDEL-SAMIEE M, Youssef MI, Elghamry F, Bazeed M, et al
    A multicentric and nationwide predictive study role of T cell sub-population in the prevalence and prognosis of cryoglobulinemia among genotype 4 chronic hepatitis C patients.
    J Med Virol. 2023;95:e29248.
    PubMed     Abstract available


  9. NGARI JW, Leumi S, Han L, Liu C, et al
    Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.
    J Med Virol. 2023;95:e29290.
    PubMed     Abstract available


    September 2023
  10. PENG X, Shi Y, Zhang B, Xu C, et al
    Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
    J Med Virol. 2023;95:e29084.
    PubMed     Abstract available


  11. LIU C, Guo M, Han L, Lu J, et al
    Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
    J Med Virol. 2023;95:e29103.
    PubMed     Abstract available


    August 2023
  12. ADACHI E, Saito M, Kikuchi T, Ikeuchi K, et al
    Incidence of sexually transmitted hepatitis C virus infection among men who have sex with men in Japan from 2009 to 2023.
    J Med Virol. 2023;95:e29039.
    PubMed     Abstract available


    July 2023
  13. LARA-AGUILAR V, Crespo-Bermejo C, Llamas-Adan M, Grande-Garcia S, et al
    HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART.
    J Med Virol. 2023;95:e28955.
    PubMed     Abstract available


  14. QU Y, Wang W, Xiao MZX, Zheng Y, et al
    The interplay between lipid droplets and virus infection.
    J Med Virol. 2023;95:e28967.
    PubMed     Abstract available


    March 2023
  15. WU B, Tobe RG, Yan M, Lin H, et al
    Trends of Global Burden Related to HBV and HCV from 1990 to 2019: An Age-Period-Cohort Analysis.
    J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28663.
    PubMed     Abstract available


  16. PISATURO M, Alessio L, Starace M, Macera M, et al
    CHARACTERIZATION OF HEPATITIS VIRUS CO-INFECTIONS IN A COHORT OF IMMIGRANTS LIVING IN SOUTHERN ITALY.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28665.
    PubMed     Abstract available


  17. FENG Z, Huang P, Zhang J, Xia X, et al
    KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28645.
    PubMed     Abstract available


    February 2023
  18. NOT A, Saludes V, Galvez M, Miralpeix A, et al
    Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
    PubMed     Abstract available


    January 2023
  19. MOHAMED AA, Esmail OE, Ibrahim AMA, Makled S, et al
    The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients.
    J Med Virol. 2023;95:e28343.
    PubMed     Abstract available


    November 2022
  20. ARANDHARA VL, Patrick McClure C, Tarr AW, Chappell S, et al
    SCAVENGER RECEPTOR CLASS B TYPE I GENETIC VARIANTS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC HEPATITIS C VIRUS INFECTION.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28331.
    PubMed     Abstract available


    September 2022
  21. ADEBOYEJO K, King B, Tsoleridis T, Tarr A, et al
    Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28178.
    PubMed     Abstract available


    August 2022
  22. PRICE AS, Nelson AK, Ghosh A, Kottilil S, et al
    A Phase 2 Open Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28105.
    PubMed     Abstract available


    July 2022
  23. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
    PubMed     Abstract available


    June 2022
  24. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    PubMed     Abstract available


    May 2022
  25. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    PubMed     Abstract available


  26. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    PubMed     Abstract available


  27. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    PubMed     Abstract available


    January 2022
  28. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    PubMed     Abstract available


    November 2021
  29. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    PubMed     Abstract available


    October 2021
  30. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    PubMed     Abstract available


    September 2021
  31. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    PubMed     Abstract available


  32. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.
    PubMed    


    August 2021
  33. ZHOU R, Liu L, Wang Y
    Viral Proteins Recognized by Different TLRs.
    J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27265.
    PubMed     Abstract available


    July 2021
  34. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    PubMed     Abstract available


    June 2021
  35. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    PubMed     Abstract available


  36. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    PubMed     Abstract available


    April 2021
  37. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    PubMed     Abstract available


    March 2021
  38. ELHENCE A, Singh A, Anand A, Kumar R, et al
    Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26971.
    PubMed     Abstract available


  39. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    PubMed     Abstract available


    December 2020
  40. MIRANDA NTGP, de Souza RL, Monteiro JC, Costa IB, et al
    Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Para, northern Brazil.
    J Med Virol. 2020 Dec 25. doi: 10.1002/jmv.26759.
    PubMed     Abstract available


    November 2020
  41. CHUA JV, Ntem-Mensah A, Abutaleb A, Husson J, et al
    Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: an open-label study.
    J Med Virol. 2020 Nov 5. doi: 10.1002/jmv.26652.
    PubMed     Abstract available


    December 2019
  42. KIM M, Kyung Lee Y, Park B, Jun Oh D, et al
    Hepatitis virus B and C infections are associated with an increased risk of non-Hodgkin lymphoma: A nested case-control study using a national sample cohort.
    J Med Virol. 2019 Dec 11. doi: 10.1002/jmv.25653.
    PubMed     Abstract available


    April 2019
  43. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.